Research and Markets: Atrial Fibrillation (Event Driven)

DUBLIN--(BUSINESS WIRE)-- Research and Markets ( has announced the addition of Decision Resources, Inc's new report "Atrial Fibrillation (Event Driven)" to their offering.

Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice. The disease poses a major public health and financial burden, and it remains an area of significant unmet need in terms of both preventing and treating the arrhythmia itself as well as its main complication: stroke. Furthermore, the opportunity for therapies that reduce stroke and agents that can maintain regular heart rhythm is expanding because of an aging population and growing awareness of the limitations of existing AF drugs. New drugs in development stand to fundamentally alter treatment patterns, reduce the burden of AF, and dramatically improve patient outcomes.

Key Topics Covered:

Executive Summary

What are the key parameters of the atrial fibrillation market?

What factors are driving the market for atrial fibrillation therapies?

What factors are constraining the market for atrial fibrillation therapies?

What are the drug development activities of note in atrial fibrillation?

What do the experts say?

What key challenges and opportunities remain?

1 Etiology and Pathophysiology

2 Epidemiology and Patient Populations

3 Current Therapies and Medical Practice

4 Unmet Needs

5 Emerging Therapies

6 Market Outlook


Tables and Figures

For more information visit

Source: Decision Resources, Inc

Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices, Pharmaceuticals

Source: Research and Markets